| 英文名称 | 中文名称 | CAS | MF |
|
Asp-Arg-Val-Tyr-Ile-His-Pro-Val-His-Leu-Leu-Tyr-Tyr-Ser
|
ASP-ARG-VAL-TYR-ILE-HIS-PRO-VAL-HIS-LEU-LEU-TYR-TYR-SER: DRVYIHPVHLLYYS
|
|
C85H123N21O21
|
|
aspartyl-seryl-aspartyl-glycyl-lysine
|
aspartyl-seryl-aspartyl-glycyl-lysine
|
125464-46-2
|
C19H32N6O11
|
|
Asp-Arg-Val-Tyr-Ile-His-Pro-Thr
|
|
|
C45H69N13O13
|
|
ASPARAGUSADSCENDENSRHIZOMEAQUEOUSEXTRACT
|
|
|
|
|
aspartyl-prolyl-glutaminyl-tyrosyl-isoleucyl-glutaminyl-seryl-arginine
|
|
130007-44-2
|
C43H67N13O15
|
|
AspartameBariumCarbonate
|
|
|
C15H18BaN2O8
|
|
Asparagine,ethylester(9CI)
|
|
764724-22-3
|
C6H12N2O3
|
|
Asparticacid,2-methyl-,4-methylester(9CI)
|
|
64298-93-7
|
C6H11NO4
|
|
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Asn
|
ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE-HIS-LEU-VAL-ILE-HIS-ASN
|
104180-23-6
|
C83H122N24O19
|
|
Asparanin B4
|
天冬宁B5
|
|
C38H62O12
|
|
aspartate carbamoyltransferse regulatory polypeptide
|
|
|
|
|
arylhydrocarbon receptor repressor
|
|
|
|
|
asparagine permease
|
|
|
|
|
Asparagine,3-fluoro-,erythro-(9CI)
|
|
72016-54-7
|
C4H7FN2O3
|
|
Asparticacid,3-fluoro-,4-methylester,erythro-(9CI)
|
|
772288-62-7
|
C5H8FNO4
|
|
Aspartame 10 μg/mL in Methanol
|
|
|
C14H18N2O5
|
|
Asp-Asp-Asp-Asp-Asp-OH
|
|
|
|
|
Asp-Asp-Asp-Asp-Asp
|
ASP-ASP-ASP-ASP-ASP
|
|
C20H27N5O16
|
|
Asp-Asp-Cys-Gly-Lys-Leu-Phe-Ser-Gly-Cys-Asp-Thr-Asn-Ala-Asp-Cys-Cys-Glu-Gly-Tyr-Val-Cys-Arg-Leu-Trp-Cys-Lys-Leu-Asp-Trp
|
|
741730-12-1
|
C144H207N39O46S6
|
|
Asp-Asp-Asp-Asp-Lys
|
|
|
|
|
Asp-Asp-Gly-Gln-Ser-Glu-Ser-Gln-Ala-Val-Asn-Gly-Lys-Thr-Gly-Ala-Ser-Glu-Ala-Val-Pro-Ser-Glu-Gly-Lys-Gly-Glu-Leu-Glu-His-Ser-Gln-Gln-Glu-Glu-Asp-Gly-Glu-Glu-Ala-Met-Ala-Gly-Pro-Pro-Gln-Gly-Leu-Phe-Pro-Gly-NH2 rat
|
|
|
|
|
Asomate W.P.(40%)
|
福美胂可湿性粉剂(40%)
|
|
C9H18AsN3S6
|
|
ARYLMERCURY
|
|
|
C5H11Hg
|
|
Atelocollagen
|
|
93685-58-6
|
|
|
arylox
|
|
24938-67-8
|
|
|
ATELOCOLLAGEN
|
缺端胶原
|
55963-88-7
|
|
|
[(1aS)-6α-[[3-O-(4-Methoxy-trans-cinnamoyl)-6-deoxy-α-L-mannopyranosyl]oxy]-1a,1bα,2,5aα,6,6aβ-hexahydro-1aβ-(hydroxymethyl)oxireno[4,5]cyclopenta[1,2-c]pyran-2α-yl]β-D-glucopyranoside
|
|
|
|
|
[(1aS)-6α-[[2-O-(4-Methoxy-trans-cinnamoyl)-6-deoxy-α-L-mannopyranosyl]oxy]-1a,1bα,2,5aα,6,6aβ-hexahydro-1aβ-(hydroxymethyl)oxireno[4,5]cyclopenta[1,2-c]pyran-2α-yl]β-D-glucopyranoside
|
|
|
|
|
Aryloxycrotonic acid
|
(2Z)-2-(3-溴苯氧基)-2-丁烯酸
|
763084-49-7
|
C9H16O3
|
|
Arylphosphateesters(unlessspecified)
|
|
|
|
|
arylphorin-binding protein
|
|
|
|
|
arylphorin
|
|
|
|
|
AspB protein
|
|
|
|
|
3-aryl-6-phenyl-1-oxa-7-azaspiro(4.5)decane
|
|
|
C19H29NO
|
|
2-arylpropionyl-CoA epimerase
|
|
|
|
|
Arylphthalamicacids
|
|
|
|
|
Arylphosphateestermix
|
|
|
|
|
ARYLPHOSPHATE
|
|
|
C5H13O4P
|
|
Arylpyrazol
|
芳基吡唑
|
121750-17-2
|
C13H9Cl3F2N4O3
|
|
Arylsulfotransferase
|
Arylsulfotransferase
|
9026-09-9
|
|
|
Arylsulfonic Acids
|
|
|
|
|
Arylsulphonyl-3-butylene-2-one
|
取代芳磺酰基-3-丁烯-2-酮
|
|
C9H16O3S
|
|
arylsulfatase E
|
|
|
|
|
Arylsulphonates
|
|
|
|
|
Arylsilatranes
|
|
|
|
|
Arylsulfonates
|
|
|
|
|
Arylsulfatases
|
|
|
|
|
arylsulfate sulfotransferase
|
arylsulfate sulfotransferase
|
158254-86-5
|
|
|
Aryltrimethylammoniumchloride
|
|
|
C8H20ClN
|
|
4-(5-aryl-1,2,3,6-tetrahydropyridino)pyrimidine
|
|
|
|
|
ARYLURAZOLE
|
|
|
C7H13N3O2
|
|
atemoyacin B
|
|
|
|
|
(β-Asp5)-Delta-Sleep Inducing Peptide
|
(Β-ASP5)-DELTA-SLEEP INDUCING PEPTIDE
|
|
|
|
A Ten.JPC palladium carbon fine chemical catalyzer
|
钯炭
|
|
Pd
|
|
(1aR,2Z,4E,5aR,8aR,9R,10aR)-1a,5a,7,8,8a,9,10,10a-Octahydro-9-[(Z)-2-hydroxymethyl-2-butenoyloxy]-4,10a-dimethyl-8-methyleneoxireno[5,6]cyclodeca[1,2-b]furan-7-one
|
|
|
|
|
Aspecioside
|
美丽马利筋苷
|
101915-75-7
|
C29H42O10
|
|
Asp-Cys-Lys-Thr-Ile-Leu-Lys-Ala-Leu-Gly-Pro-Ala-Ala-Thr-Leu-Glu
|
|
|
C72H126N18O23S
|
|
Atenolol (RS)-
|
|
|
C14H22N2O3
|
|
Atenolol for system suitability
|
|
|
C14H22N2O3
|
|
Atenolol-beta-cyclodextrin complex
|
|
|
|
|
Asp-Cys-Ala-Trp-Leu-Glu-Ala-Gln-Glu-Glu-Glu-Glu-Val-Gly
|
|
|
C67H98N16O28S
|
|
ATENOLOL-D6
|
|
|
C14H16D6N2O3
|
|
Atenolol
|
阿替洛尔
|
29122-68-7
|
C14H22N2O3
|
|
ATENOLOL FOR COLUMN VALIDATION EPA(CRM STANDARD)
|
|
|
C14H22N2O3
|
|
Atenolol imp. A (EP):2-(4-hydroxyphenyl)acetamide mm(CRM standard)
|
|
|
|
|
ATENOLOL MM(CRM STANDARD)
|
|
|
C14H22N2O3
|
|
ATENOLOL IMPURITY STANDARD BP STANDARD(CRM STANDARD)
|
|
|
C14H22N2O3
|
|
ATENOLOL USP(CRM STANDARD)
|
|
|
C14H22N2O3
|
|
Atenolol imp. D (EP): 2-[4-(3-chloro-2-hydroxypropoxy)phenyl]acetamide mm(CRM standard)
|
|
|
|
|
Atenolol100Mg
|
|
|
|
|
AtenololTablets
|
|
|
|
|
Atenolol(S)-
|
|
|
C14H22N2O3
|
|
Atenolol USP PH EUR
|
|
|
C14H22N2O3
|
|
Atenolol Ph Eur
|
|
|
|
|
Atenolol B.P
|
|
|
|
|
Atenolol-d7 (iso-propyl-d7)
|
|
|
C14H15D7N2O3
|
|
Atenolol imp. G (EP): 4-(2-hydroxy-3-isopropylaminopropoxy)phenylacetic acid mm(CRM standard)
|
|
|
|
|
ATENOLOL IMPURITY STANDARD
|
阿替洛尔杂质标准品[Β受体阻滞药]
|
|
C14H22N2O3
|
|
ATENOLOL-D7
|
阿替洛尔D7
|
1202864-50-3
|
C14H15D7N2O3
|
|
Atenolol hydrochloride
|
|
|
C14H23ClN2O3
|
|
ATENOLOL FOR COLUMN VALIDATION
|
|
|
C14H22N2O3
|
|
ATENOLOL HCL
|
|
|
C14H23ClN2O3
|
|
Atenolol impurity C (EP)2-[4-(2,3-epoxypropoxy]phenyl]acetamide mm(CRM standard)
|
|
|
|
|
Atenolol imp. B (EP): 2-[4-(2,3-dihydroxypropoxy)phenyl]acetamide mm(CRM standard)
|
|
|
|
|
Atenolol-β-cyclodextrin complex
|
|
|
|
|
Atenolol impurity F (EP):(4,4'-[N-isopropyl-3,3'-iminobis(2-hydroxypropoxy)]-bis(2-phenylacetamide))store long term at -20 °C mm(CRM standard)
|
|
|
C14H22N2O3
|
|
Atenolol imp. H (EP):4-(2-hydroxy-3-isopropylaminopropoxy)phenylacetonitrile mm(CRM standard)
|
|
|
|
|
Atenolol imp. E (EP): 4,4'-(2-hydroxy-1,3-propandiyldioxy)bis(2-phenylacetamide) mm(CRM standard)
|
|
|
|
|
ATENOLOL BP STANDARD(CRM STANDARD)
|
|
|
|
|
ATENOLOL, [RING-3H]-
|
阿替洛尔
|
|
C14H21N2O3T
|
|
Atenolol for systeM suitability(5Mg)
|
|
|
C14H22N2O3
|
|
Asp ei
|
|
|
|
|
ASP EIA Kit
|
ASP EIA Kit
|
|
|
|
Asp f 3 allergen
|
|
|
|
|
Asp f 4 allergen
|
|
|
|
|
Asp f 6 allergen
|
|
|
|
|
ASPEN
|
Aspen
|
|
|
|
ASPENLEAF
|
|
|
|
|
(6aS)-1-Pentyl-3-hydroxy-6,6,9β-trimethyl-6aα,7,8,9,10,10aα-hexahydro-6H-dibenzo[b,d]pyran
|
|
|
|
|
(6aS)-3-Pentyl-6,6,9-trimethyl-6aβ,7,10,10aα-tetrahydro-6H-dibenzo[b,d]pyran-1,7β-diol
|
|
|
|